US6231881B1
(en)
*
|
1992-02-24 |
2001-05-15 |
Anton-Lewis Usala |
Medium and matrix for long-term proliferation of cells
|
US5981505A
(en)
|
1993-01-26 |
1999-11-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for delivery of genetic material
|
WO1995003843A1
(en)
|
1993-07-30 |
1995-02-09 |
The Regents Of The University Of California |
Endocardial infusion catheter
|
US5837533A
(en)
|
1994-09-28 |
1998-11-17 |
American Home Products Corporation |
Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
|
US5840710A
(en)
|
1994-12-09 |
1998-11-24 |
Genzyme Corporation |
Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
US6416510B1
(en)
|
1997-03-13 |
2002-07-09 |
Biocardia, Inc. |
Drug delivery catheters that attach to tissue and methods for their use
|
US6217900B1
(en)
|
1997-04-30 |
2001-04-17 |
American Home Products Corporation |
Vesicular complexes and methods of making and using the same
|
JP2002510319A
(ja)
|
1997-07-01 |
2002-04-02 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
US6749617B1
(en)
|
1997-11-04 |
2004-06-15 |
Scimed Life Systems, Inc. |
Catheter and implants for the delivery of therapeutic agents to tissues
|
US6833361B2
(en)
|
1998-05-26 |
2004-12-21 |
Ribapharm, Inc. |
Nucleosides having bicyclic sugar moiety
|
SK17432000A3
(sk)
|
1998-05-26 |
2001-07-10 |
Icn Pharmaceuticals, Inc. |
Zlúčenina, ktorá zahŕňa nukleozid s 2',4'-mostíkom a oligonukleotid z nej odvodený
|
DE60045706D1
(de)
|
1999-03-18 |
2011-04-21 |
Exiqon As |
Detektion von genmutationen mittels lna primer
|
AU7406600A
(en)
|
1999-10-04 |
2001-05-10 |
Exiqon A/S |
A method of increasing the specificity of oxy-lna oligonucleotides
|
US6998484B2
(en)
|
2000-10-04 |
2006-02-14 |
Santaris Pharma A/S |
Synthesis of purine locked nucleic acid analogues
|
EP2428570B1
(en)
|
2001-09-28 |
2018-05-23 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Microrna molecules
|
EP2298358A1
(en)
|
2002-05-06 |
2011-03-23 |
Alnylam Pharmaceuticals Inc. |
Methods for delivery of nucleic acids
|
US20080214437A1
(en)
|
2002-09-06 |
2008-09-04 |
Mohapatra Shyam S |
Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
|
EP3222722B1
(en)
|
2002-11-18 |
2019-04-10 |
Roche Innovation Center Copenhagen A/S |
Antisense design
|
WO2005013901A2
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
WO2005017145A1
(ja)
|
2003-08-13 |
2005-02-24 |
Japan Biological Informatics Consortium |
機能性rnaが制御する被制御遺伝子の同定・予測方法及びその利用方法
|
WO2005078096A2
(en)
|
2004-02-09 |
2005-08-25 |
University Of Massachusetts |
Dual functional oligonucleotides for use in repressing mutant gene expression
|
EP2295604B1
(en)
|
2004-02-09 |
2015-04-08 |
Thomas Jefferson University |
Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
|
AU2005214904B2
(en)
|
2004-02-13 |
2011-07-21 |
Rockefeller University |
Anti-microRNA oligonucleotide molecules
|
US20060148742A1
(en)
|
2004-02-26 |
2006-07-06 |
Kaye David M |
Polynucleotide delivery to cardiac tissue
|
US7722596B2
(en)
|
2004-02-26 |
2010-05-25 |
Osprey Medical, Inc. |
Regional cardiac tissue treatment
|
CA2557480A1
(en)
|
2004-02-26 |
2005-09-09 |
V-Kardia Pty Ltd |
Isolating cardiac circulation
|
US20070203445A1
(en)
|
2004-02-26 |
2007-08-30 |
V-Kardia Pty Ltd |
Isolating cardiac circulation
|
EP2290076B1
(en)
|
2004-05-28 |
2015-03-25 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
ES2507544T3
(es)
|
2004-11-12 |
2014-10-15 |
Asuragen, Inc. |
Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
|
US9550990B2
(en)
|
2004-12-10 |
2017-01-24 |
Ionis Pharmaceuticals, Inc. |
Regulation of epigenetic control of gene expression
|
US20060185027A1
(en)
|
2004-12-23 |
2006-08-17 |
David Bartel |
Systems and methods for identifying miRNA targets and for altering miRNA and target expression
|
EP1838870A2
(en)
|
2004-12-29 |
2007-10-03 |
Exiqon A/S |
NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
|
US8071306B2
(en)
|
2005-01-25 |
2011-12-06 |
Merck Sharp & Dohme Corp. |
Methods for quantitating small RNA molecules
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
US9085774B2
(en)
|
2005-04-19 |
2015-07-21 |
Basf Plant Science Gmbh |
Methods controlling gene expression
|
US10000757B2
(en)
|
2005-05-27 |
2018-06-19 |
Ospedale San Raffaele S.R.L. |
Gene vector
|
US20090209621A1
(en)
|
2005-06-03 |
2009-08-20 |
The Johns Hopkins University |
Compositions and methods for decreasing microrna expression for the treatment of neoplasia
|
CA2889540A1
(en)
|
2005-09-15 |
2007-03-22 |
Marina Biotech, Inc. |
Improvements in or relating to amphoteric liposomes
|
JP2009519339A
(ja)
|
2005-12-12 |
2009-05-14 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
筋細胞増殖及び分化を調節するマイクロrna
|
EP2388328A1
(en)
|
2006-01-27 |
2011-11-23 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of micrornas
|
MX2008012219A
(es)
|
2006-04-03 |
2008-10-02 |
Santaris Pharma As |
Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
|
ES2434075T3
(es)
|
2006-07-13 |
2013-12-13 |
The Ohio State University Research Foundation |
MIR-203 para el diagnóstico de adenocarcinoma de colon con mal pronóstico de supervivencia
|
WO2008014008A2
(en)
|
2006-07-28 |
2008-01-31 |
The Johns Hopkins University |
Compositions and methods for modulating angiogenesis
|
EP2434017A3
(en)
|
2006-08-01 |
2012-09-05 |
Board of Regents of the University of Texas System |
Identification of a micro-RNA that activates expression of beta-myosin heavy chain
|
WO2008042231A2
(en)
|
2006-09-29 |
2008-04-10 |
Children's Medical Center Corporation |
Compositions and methods for evaluating and treating heart failure
|
EP2094869B1
(de)
|
2006-10-09 |
2012-07-25 |
Julius-Maximilians-Universität Würzburg |
Microrna (mirna) zur diagnose und therapie von herzerkrankungen
|
WO2008147430A2
(en)
|
2006-10-11 |
2008-12-04 |
Nucleonics, Inc. |
Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
|
AU2007323469B2
(en)
|
2006-11-23 |
2014-07-24 |
Guangdong Maijinjia Biotechnology Co., Ltd |
Oligonucleotides for modulating target RNA activity
|
WO2008070082A2
(en)
|
2006-12-04 |
2008-06-12 |
The Johns Hopkins University |
Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
|
BRPI0719995A2
(pt)
|
2006-12-14 |
2014-03-18 |
Novartis Ag |
Composições e métodos para tratar distúrbios musculares & cardiovasculares
|
WO2008074328A2
(en)
|
2006-12-21 |
2008-06-26 |
Exiqon A/S |
Microrna target site blocking oligos and uses thereof
|
EP3536788A1
(en)
|
2006-12-21 |
2019-09-11 |
QIAGEN GmbH |
Microrna target site blocking oligos and uses thereof
|
DK2149605T3
(da)
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
WO2008131191A2
(en)
|
2007-04-20 |
2008-10-30 |
Amgen Inc. |
Nucleic acids hybridizable to micro rna and precursors thereof
|
US8841267B2
(en)
|
2007-05-23 |
2014-09-23 |
Ge Healthcare Dharmacon, Inc. |
Micro-RNA scaffolds, non-naturally occurring micro-RNAs, and methods for optimizing non-naturally occurring micro-RNAs
|
WO2009004632A2
(en)
|
2007-07-05 |
2009-01-08 |
Yeda Research And Development Co. Ltd. |
Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation
|
AU2008275877B2
(en)
|
2007-07-18 |
2015-01-22 |
The Regents Of The University Of Colorado, A Body Corporate |
Differential expression of microRNAs in nonfailing versus failing human hearts
|
NZ583025A
(en)
|
2007-07-31 |
2012-06-29 |
Univ Texas |
Micro-rnas that control myosin expression and myofiber identity
|
WO2009026576A1
(en)
|
2007-08-23 |
2009-02-26 |
Keren Pharmaceuticals |
Targeting rna with external guide sequences
|
WO2009036236A1
(en)
|
2007-09-14 |
2009-03-19 |
The Ohio State University Research Foundation |
Mirna expression in human peripheral blood microvesicles and uses thereof
|
NZ583677A
(en)
|
2007-10-04 |
2012-06-29 |
Santaris Pharma As |
MicroRNAs comprising Locked Nucleic Acid (LNA) units
|
WO2009058818A2
(en)
|
2007-10-29 |
2009-05-07 |
The Board Of Regents Of The University Of Texas System |
Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
|
DE102007052114B4
(de)
*
|
2007-10-30 |
2011-01-05 |
T2Cure Gmbh |
Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
|
CN101424640B
(zh)
|
2007-11-02 |
2012-07-25 |
江苏命码生物科技有限公司 |
血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法
|
CN101951924B
(zh)
|
2007-11-09 |
2015-06-24 |
得克萨斯系统大学董事会 |
Mir-15家族的微小rna调控心肌细胞存活和心脏修复
|
AU2008335718A1
(en)
*
|
2007-12-11 |
2009-06-18 |
Coda Therapeutics, Inc. |
Impaired wound healing compositions and treatments
|
JP2011512326A
(ja)
|
2007-12-31 |
2011-04-21 |
ナノコア セラピューティクス,インコーポレイテッド |
心不全の治療用のrna干渉
|
EP2096171A1
(en)
|
2008-02-27 |
2009-09-02 |
Julius-Maximilians-Universität Würzburg |
MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
|
US20110160285A1
(en)
|
2008-03-13 |
2011-06-30 |
The Regents Of The University Of Colorado |
Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy
|
US20090326049A1
(en)
|
2008-04-04 |
2009-12-31 |
Alexander Aristarkhov |
Blocking oligos for inhibition of microrna and sirna activity and uses thereof
|
EP2297322A1
(en)
|
2008-06-04 |
2011-03-23 |
The Board of Regents of The University of Texas System |
Modulation of gene expression through endogenous small rna targeting of gene promoters
|
US20110152352A1
(en)
|
2008-06-10 |
2011-06-23 |
Tufts University |
Smad proteins control drosha-mediated mirna maturation
|
DK2310505T3
(en)
|
2008-06-30 |
2017-10-16 |
Roche Innovation Ct Copenhagen As |
ANTIDOT oligomers
|
CN101386848A
(zh)
|
2008-08-12 |
2009-03-18 |
南京大学 |
细胞微粒子所载微小核糖核酸及其制备研究方法和应用
|
EP3067359A1
(en)
|
2008-09-23 |
2016-09-14 |
Scott G. Petersen |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
|
EP2358398A2
(en)
|
2008-10-24 |
2011-08-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
MX2011008190A
(es)
|
2009-02-04 |
2011-10-06 |
Univ Texas |
Direccionamiento dual de mir-208 y mir-499 en el tratamiento de trastornos cardiacos.
|
WO2010093788A2
(en)
|
2009-02-11 |
2010-08-19 |
Dicerna Pharmaceuticals, Inc. |
Multiplex dicer substrate rna interference molecules having joining sequences
|
US20110086348A1
(en)
|
2009-02-19 |
2011-04-14 |
The Cleveland Clinic Foundation |
Method for assessing heart disease
|
JP5883381B2
(ja)
|
2009-05-05 |
2016-03-15 |
ミラゲン セラピューティクス,インコーポレイテッド |
親油性ポリヌクレオチド接合体
|
AU2010249482A1
(en)
|
2009-05-20 |
2012-01-12 |
Board Of Regents, The University Of Texas System |
Identification of micro-RNAs involved in post-myocardial infarction remodeling and heart failure
|
MA33488B1
(fr)
|
2009-06-08 |
2012-08-01 |
Miragen Therapeutics |
Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
|
US20120214863A1
(en)
*
|
2009-08-05 |
2012-08-23 |
The Ohio State University Research Foundation |
Anti-miR-1 Therapy for Wound Healing
|
DK2475372T4
(da)
|
2009-09-10 |
2020-11-30 |
Velin Pharma As |
Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse
|
EP2490699A1
(en)
|
2009-10-20 |
2012-08-29 |
Santaris Pharma A/S |
Oral delivery of therapeutically effective lna oligonucleotides
|
US8592151B2
(en)
|
2009-11-17 |
2013-11-26 |
Musc Foundation For Research Development |
Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids
|
US20130109738A1
(en)
|
2010-02-24 |
2013-05-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Control of Cardiac Growth, Differentiation and Hypertrophy
|
US20130079505A1
(en)
|
2010-03-24 |
2013-03-28 |
Mirrx Therapeutics A/S |
Bivalent antisense oligonucleotides
|
EP2371370A1
(en)
|
2010-04-01 |
2011-10-05 |
Johann Wolfgang Goethe-Universität Frankfurt am Main |
Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms and atherosclerotic plaque destabilization
|
US9821009B2
(en)
|
2010-04-13 |
2017-11-21 |
Jiangsu Mingma Biotech Co., Ltd. |
Method for modulating microRNA content in living beings and the use thereof
|
WO2011131354A1
(en)
|
2010-04-20 |
2011-10-27 |
Febit Holding Gmbh |
Complex mirna sets as novel biomarkers for an acute coronary syndrome
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
US20130150256A1
(en)
|
2010-06-11 |
2013-06-13 |
Jane Synnergren |
Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types
|
ITMI20101089A1
(it)
|
2010-06-16 |
2011-12-17 |
Istituto Naz Di Genetica Molecolare Ingm |
Profili di espressione di micro-rna nel sangue periferico per il monitoraggio del sistema immunitario
|
WO2012006181A2
(en)
|
2010-06-29 |
2012-01-12 |
Mount Sinai School Of Medicine |
Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
|
WO2012006577A2
(en)
|
2010-07-08 |
2012-01-12 |
Duke University |
Direct reprogramming of cells to cardiac myocyte fate
|
WO2012018866A2
(en)
|
2010-08-03 |
2012-02-09 |
University Of South Alabama |
Methods and compositions for the diagnosis and treatment of breast cancer
|
WO2012020307A2
(en)
|
2010-08-13 |
2012-02-16 |
The University Court Of The University Of Glasgow |
Therapeutic uses of microvesicles and related micrornas
|
EP2609198B8
(en)
|
2010-08-24 |
2018-03-28 |
Sirna Therapeutics, Inc. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
US9290760B2
(en)
|
2010-09-15 |
2016-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
CN103492569B
(zh)
|
2010-11-05 |
2020-04-07 |
米拉根医疗公司 |
碱基经修饰的寡核苷酸
|
WO2012065024A1
(en)
*
|
2010-11-11 |
2012-05-18 |
University Of Miami |
Compositions, cells, kits and methods for autologous stem cell therapy
|
AU2011343720A1
(en)
|
2010-12-15 |
2013-04-11 |
Miragen Therapeutics |
MicroRNA inhibitors comprising locked nucleotides
|
WO2012149646A1
(en)
|
2011-05-05 |
2012-11-08 |
Sunnybrook Research Institute |
Mirna inhibitors and their uses
|
JP6177243B2
(ja)
|
2011-10-06 |
2017-08-09 |
ミラゲン セラピューティクス, インコーポレイテッド |
マイクロrnaの調節による全身エネルギーホメオスタシスの制御
|
GB201117482D0
(en)
|
2011-10-11 |
2011-11-23 |
Univ Dundee |
Targetiing of miRNA precursors
|
EP2584040A1
(en)
|
2011-10-17 |
2013-04-24 |
Pharmahungary 2000 Kft. |
Compounds for treatment of ischemic injury
|
CN107266391B
(zh)
|
2011-10-18 |
2020-04-17 |
迪克纳制药公司 |
胺阳离子脂质及其用途
|
DK2790736T3
(en)
|
2011-12-12 |
2018-05-07 |
Oncoimmunin Inc |
In vivo delivery of oligonucleotides
|
EP2791337A1
(en)
|
2011-12-15 |
2014-10-22 |
Oncostamen S.r.l. |
Micrornas and uses therof
|
EP2604690A1
(en)
|
2011-12-15 |
2013-06-19 |
Oncostamen S.r.l. |
MicroRNAs and uses thereof
|
FR2984358A1
(fr)
|
2011-12-16 |
2013-06-21 |
Genethon |
Methodes pour le diagnostic de dystrophies musculaires
|
KR101928418B1
(ko)
|
2012-06-21 |
2018-12-12 |
미라젠 세러퓨틱스 인코포레이티드 |
잠금 핵산 모티프를 포함하는 올리고뉴클레오티드-기반 억제제
|
US9163235B2
(en)
|
2012-06-21 |
2015-10-20 |
MiRagen Therapeutics, Inc. |
Inhibitors of the miR-15 family of micro-RNAs
|
ES2606636T3
(es)
*
|
2013-01-24 |
2017-03-24 |
Pierre Fabre Médicament S.A.S. |
Composición que comprende un antagomir encapsulado
|
WO2015066611A2
(en)
|
2013-11-01 |
2015-05-07 |
The Trustees Of Columbia University In The City Of New York |
Microrna profiles in heart failure: methods and systems for detection and use
|
AU2016209386A1
(en)
|
2015-01-20 |
2017-08-03 |
MiRagen Therapeutics, Inc. |
miR-92 inhibitors and uses thereof
|
SG10201910479UA
(en)
|
2015-05-08 |
2020-03-30 |
Agency Science Tech & Res |
Method for diagnosis and prognosis of chronic heart failure
|
EP3601565A4
(en)
|
2017-03-25 |
2021-01-06 |
Miragen Therapeutics, Inc. |
MIR-92 INHIBITORS IN THE TREATMENT OF HEART FAILURE
|